|1.||El-Etreby, Shahira: 1 article (02/2013)|
|2.||Arafa, Mona M: 1 article (02/2013)|
|3.||El-Alfy, Hatem A: 1 article (02/2013)|
|4.||Goda, Inas F: 1 article (02/2013)|
|5.||Ali, Rabab M: 1 article (02/2013)|
|6.||Saudy, Niveen S: 1 article (02/2013)|
|7.||Farag, Raghda E: 1 article (02/2013)|
|8.||Eldeek, Basem S: 1 article (02/2013)|
|9.||Seszták, Magdolna: 1 article (12/2006)|
|10.||Bosák, Vladimir: 1 article (12/2006)|
|1.||Pemphigus (Pemphigus Vulgaris)
09/15/1997 - "Previous studies showed that almost all Ashkenazi Jewish patients with pemphigus vulgaris carried the extended haplotype [HLA-B38, SC21, DRB1*0402, DQB1*0302] or [HLA-B35, SC31, DRB1*0402, DQB1*0302] or class II fragments of them. "
04/01/2004 - "Studies showed that the associated HLA haplotype in Jewish pemphigus vulgaris (PV) patients is HLA-B38, DRB1*0402, and DQB1*0302; or HLA-B35, DRB1*0402, and DQB1*0302. "
06/01/1991 - "Previous studies demonstrated that HLA-DR4 was markedly increased among Ashkenazi Jewish patients with pemphigus vulgaris (PV), almost entirely as the common Jewish extended haplotype [HLA-B38, SC21, DR4, DQw8] or as the haplotype HLA-B35, SC31, DR4, DQw8, and that HLA-DR4, DQw8 was distributed among patients in a manner consistent with dominant expression of a class II (D-region or D-region-linked) susceptibility gene. "
10/01/1990 - "The incidence of HLA-B38, DR4, DQw3 was significantly increased in patients with agranulocytosis (five of five patients) compared with control patients of Ashkenazi Jewish ancestry (two of 17 patients). "
02/01/1998 - "= 1, P = 0.11), although the agranulocytosis patients had a higher frequency of the HLA B38 antigen (8/11 or 72% vs. 6/50 or 12%; chi 2 = 18.7, d.f. "
02/01/1998 - "HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients."
04/01/1992 - "HLA-B38 and clozapine-induced agranulocytosis."
01/01/1992 - "An association between the HLA-B38, -DR4, -DQw3 haplotype and clozapine-induced agranulocytosis was found in all Jewish cases (7/7; 100%); in contrast only 4 of 21 (19%) Jewish control (nonagranulocytic) patients carried this haplotype. "
|4.||T-Cell Leukemia (Leukemia, T Cell)
02/01/2013 - "On logistic regression analysis, presence of the HLA-A01 allele was associated with SVR (OR: 0.50; 95% CI: 0.28-0.89; P = 0.02) and HLA-B38 can predict non response to therapy (OR: 7.92; 95% CI: 1.67-37.54; P = 0.009) with an overall accuracy of 60%.Severe fibrosis (OR: 3.035; 95% CI: 1.521-6.091; P = 0.002), high viremia (OR: 2.69; 95% CI: 1.11-6.53; P = 0.005) and steatosis (OR: 2.1; 95% CI: 1.002-3.90; P = 0.041) predicted no response with an overall accuracy of 81.8%. HLA-A01 and HLA-B38 alleles are associated with and may have a role in the outcome of response to Peg-IFN plus ribavirin therapy in Egyptian patients diagnosed with chronic HCV infection. "
|1.||HLA-B35 Antigen (HLA B35 Antigen)
|2.||HLA-DR4 Antigen (HLA DR4 Antigen)
|5.||HLA-DR2 Antigen (HLA DR2 Antigen)
|6.||HLA-A2 Antigen (HLA A2 Antigen)
|7.||HLA-A Antigens (HLA-A)